| buprenorphine/naloxone sublingual film / Generic mfg. |
ACTRN12614000161628: A study exploring the ease with which placebo Suboxone sublingual films can be removed from the mouth after specified times, when administered stacked on top of each other compared to spaced out around the mouth. |
|
|
| Not yet recruiting | 4 | 42 | | | South Eastern Sydney Local Health District, Reckitt Benckiser Pty Ltd. | Opioid dependence | | | | |
2009-012814-36: Buprenorfiini-naloksoni ja metadoni erilaisissa psykososiaalisissa hoito-ohjelmissa buprenorfiiniriippuvaisten korvaushoidossa. Satunnaistettu kontrolloitu tutkimus |
|
|
| Ongoing | 4 | 100 | Europe | metadoni, , Oral solution, Suboxone | Helsingin Diakonissalaitos | Opioidiriippuvuus, buptenorfiinin suonensisäinen väärinkäyttö | | | | |
2007-002352-41: Lyhyt ja pitkä buprenorfiini-naloksoni -hoito suonensisäisen buprenorfiiniriippuvuuden vieroitushoidossa. Satunnaistettu kontrolloitu tutkimus |
|
|
| Ongoing | 4 | 120 | Europe | Suboxone, BritLofex | Helsingin Diakonissalaitos | Opiaattiriippuvuus, buprenorfiinin suonensisäinen väärinkäyttö | | | | |
2021-001817-35: Treatment of opioid dependency in patients with chronic pain: a comparative study between suboxone and methadone. Behandeling van opiaatafhankelijkheid bij pijn: een vergelijkende studie met suboxone en methadon. |
|
|
| Ongoing | 4 | 100 | Europe | Methadone, Sublingual tablet, Tablet, Suboxone, Methadone | Radboud University Medical Center, Dutch Research Council (NWO) | Opioid use disorder Stoornis in het opioïdgebruik, Dependence on opioids Afhankelijkheid aan opiaten, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04716413: Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment |
|
|
| Terminated | 4 | 3 | US | Dsuvia | Montefiore Medical Center | Acute Pain | 11/22 | 11/22 | | |
NCT04091009: A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms |
|
|
| Not yet recruiting | 4 | 76 | NA | Buprenorphine, Subutex, Buprenorphine/naloxone, Suboxone | Massachusetts General Hospital | Opioid-use Disorder, Opioid Use Disorder, Mild | 12/22 | 12/23 | | |
NCT04771689: Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients |
|
|
| Not yet recruiting | 4 | 60 | US | Buprenorphine/Naloxone, Suboxone | Massachusetts General Hospital | Post-operative Pain | 12/22 | 12/22 | | |
NCT04283500: Buprenorphine Loading in the Emergency Department |
|
|
| Completed | 4 | 15 | US | Buprenorphine Naloxone, Suboxone | NYU Langone Health, Emergency Medicine Foundation | Opioid-use Disorder | 02/23 | 02/23 | | |
2022-003925-23: The discontinuation of pain medication in patients with failed back surgery, treated with spinal cord stimulation. |
|
|
| Not yet recruiting | 4 | 195 | Europe | Tablet, Concentrate and solvent for solution for injection/infusion, Sublingual tablet, Orodispersible tablet, Catapressan 150µg tablets, Catapressan 150µg/1ml solution for injection, Suboxone 2mg/0,5mg sublingual tablets, Suboxone 8mg/2mg sublingual tablets, Libroxar 2mg/0,5mg sublingual tablets, Libroxar 8mg/2mg sublingual tablets, OxyNorm Instant 5mg orodispersible tablets, OxyNorm Instant 10mg orodispersible tablets, OxyNorm Instant 20mg orodispersible tablets | Vrije Universiteit Brussel, Vrije Universiteit Brussel | Persistent spinal pain syndrome type 2, Persisting Spinal Pain Syndrome Type II is a condition in whichpatients are suffering from persistent low back pain, despite previously performed surgical interventions., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
STOPIT, NCT05594121: Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder |
|
|
| Not yet recruiting | 4 | 90 | Canada | Extended Release Subcutaneous Buprenorphine, Sublocade, Immediate Release Sublingual Buprenorphine, Suboxone | Royal Victoria Hospital, Canada | Moderate to Severe Opioid Use Disorder | 12/23 | 12/24 | | |
| Enrolling by invitation | 4 | 1500 | US | Suboxone, Brief counseling in the ED, Referral to outpatient treatment, Follow-up coaching | The University of Texas Health Science Center, Houston | Opioid Use Disorder | 08/25 | 08/25 | | |
| Recruiting | 4 | 15 | US | Buprenorphine, Naloxone Drug Combination, Suboxone, Individual Counseling, Therapy, Peer Recovery Support Services, Peer Coaching, Recovery Coaching, Support Group, Group Therapy, Referral to Medication Management, Assertive Outreach, Community Outreach | The University of Texas Health Science Center, Houston | Opioid-use Disorder, Opioid Dependence, Opioid Overdose, Opioid Use, Substance Use Disorders | 08/26 | 08/27 | | |
NCT05944952: Low-dose Versus a High-dose Sublingual Buprenorphine Induction |
|
|
| Recruiting | 4 | 40 | US | buprenorphine/naloxone, suboxone | Friends Research Institute, Inc., MATClinics | Opioid Use Disorder | 10/24 | 12/24 | | |
NCT06726200: A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use |
|
|
| Not yet recruiting | 4 | 60 | US | Buprenorphine + naloxone (Suboxone), Buprenorphine Injection | Rachel R. Luba, National Institute on Drug Abuse (NIDA) | Opioid Use Disorder | 01/29 | 01/29 | | |
2018-004460-63: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO) |
|
|
| Not yet recruiting | 3 | 600 | Europe | Sublocade, Buprenorphine, METHADONE, Buprenorphine-Naloxone, Espranor Oral lyophilisate, RBP-6000, Solution for infusion in pre-filled syringe, Sublingual tablet, Oral liquid, Oral lyophilisate, SUBOXONE, Espranor | South London and Maudsley NHS Foundation Trust, King's College London, INDIVIOR UK | Opiod addiction, Opiod Addiction, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 3 | 9 | US | Buprenorphine, Naloxone, Suboxone, Buprenex, Subutex | Yale University, United States Department of Defense | Opioid Dependence | 02/22 | 01/23 | | |
| Completed | 3 | 342 | Europe | Buprenorphine Injectable Product, Sublocade®; prev. RBP-60000, Methadone, Buprenorphine, Suboxone, Espranor, Subutex | King's College London, South London and Maudsley NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Cumbria, Northumberland Tyne and Wear NHS Foundation Trust, Birmingham and Solihull Mental Health NHS Foundation Trust, NHS Tayside, Bangor University | Opiate Substitution Treatment | 04/22 | 03/23 | | |
MOMs-CMA, NCT03911466: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study |
|
|
| Active, not recruiting | 3 | 97 | US | Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone | T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC | Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy | 01/25 | 01/25 | | |
| Active, not recruiting | 3 | 140 | US | Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone | T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC | Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy | 01/25 | 01/25 | | |
MOMs-INO, NCT03911739: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study |
|
|
| Recruiting | 3 | 200 | US | Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone | T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC | Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy | 01/25 | 01/25 | | |
| Active, not recruiting | 2/3 | 250 | US | buprenorphine/naloxone oral product, Suboxone, injectable naltrexone, Vivitrol, Pharmacy maintenance addiction care, oral naltrexone | Lifespan, University of Rhode Island, The Miriam Hospital | Opioid-use Disorder | 09/22 | 10/22 | | |
NCT04893525: Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments |
|
|
| Recruiting | 2/3 | 658 | Canada | Buprenorphine/naloxone, Suboxone | University of British Columbia | Opioid-use Disorder | 12/24 | 06/25 | | |
| Enrolling by invitation | 2/3 | 360 | US | Patient Navigation, Buprenorphine, Buprenorphine/naloxone sublingual film | Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA), Baltimore City Health Department | Opioid-use Disorder | 07/25 | 12/25 | | |
NCT03291847: Maternal Buprenorphine-naloxone Treatment and the Infant |
|
|
| Completed | 2 | 42 | US | fetal monitoring, maternal physiology monitoring, Buprenorphine Naloxone, Suboxone | Johns Hopkins University, National Institute on Drug Abuse (NIDA) | Maternal Opioid Use Disorder, Opioid Exposed Infant | 12/22 | 12/23 | | |
NCT04234191: Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder |
|
|
| Recruiting | 2 | 50 | Canada | Buprenorphine/naloxone, Suboxone, Hydromorphone, Dihydromorphinone, Dilaudid | University of British Columbia, Vancouver Coastal Health | Opioid Use Disorder | 01/25 | 01/25 | | |
NCT06406400: Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2). |
|
|
| Terminated | 2 | 15 | US | AZD4041, Itraconazole, Sporanox®, Buprenorphine, Belbuca®, Buprenorphine / Naloxone, Suboxone®, Hydromorphone, Dilaudid®, Placebo | AstraZeneca, Parexel | Opioid Use Disorder | 07/24 | 07/24 | | |
AMOHI-1, NCT04480554: Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1 |
|
|
| Recruiting | 2 | 225 | US, RoW | Methadone, Buprenorphine/naloxone, Suboxone, XR-Naltrexone, Vivitrol | University of Pennsylvania, National Institute of Drug Abuse, The Wistar Institute, Institute of Applied Medicine and Epidemiology (IMEA), Ho Chi Minh City CDC | Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment | 06/25 | 06/25 | | |
BOPAT, NCT04677114: Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections |
|
|
| Recruiting | 2 | 90 | US | Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Suboxone or Sublocade, Buprenorphine and standard of care antibiotic treatment | Laura Fanucchi, National Institute on Drug Abuse (NIDA) | Drug Use, Opioid-use Disorder | 05/25 | 08/25 | | |
| Recruiting | 2 | 122 | US | INDV-6001, Suboxone, Sublocade | Indivior Inc. | Moderate to Severe Opioid Use Disorder | 10/25 | 10/25 | | |
PEDsTREATOUD, NCT04737603: Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder |
|
|
| Withdrawn | 2 | 24 | NA | ED-Initiated treatment with buprenorphine / naloxone, Suboxone | University of California, Davis, Yale University, University of Utah | Opioid-use Disorder | 07/25 | 07/25 | | |
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) |
|
|
| Recruiting | 2 | 2190 | US | SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD | NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC | Opioid Use Disorder (OUD) | 07/26 | 12/26 | | |
NCT04976855: Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder |
|
|
| Completed | 1 | 64 | US | INDV-2000, C4X_3256, Placebo, SUBOXONE® sublingual film, Buprenorphine and naloxone | Indivior Inc., National Institute on Drug Abuse (NIDA) | Healthy Volunteer, Opioid-use Disorder | 07/23 | 07/23 | | |
| Completed | N/A | 17 | US | Suboxone, Buprenorphine Naloxone, Truvada, Pre-Exposure Prophylaxis (PrEP), Mavyret, Hepatitis C treatment | Duke University, Center for AIDS Research (CFAR), National Institute of Allergy and Infectious Diseases (NIAID) | Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C | 03/23 | 03/23 | | |
| Recruiting | N/A | 10 | US | Addinex | Addinex Technologies, Inc., Centers for Disease Control and Prevention | Opioid Use Disorder, Opioid Withdrawal | 12/24 | 12/24 | | |
BBB, NCT05872386: "Bupe by the Book": A Tele-Buprenorphine Clinical Trial in Public Libraries With Unstably Housed Persons With Opioid Use Disorder |
|
|
| Recruiting | N/A | 60 | US | Buprenorphine uptake/retention via Telehealth, Control group | University of California, San Diego, San Diego State University | Telehealth at the Library, Control Group | 06/24 | 06/24 | | |
